Abstract:Introduction: Multiple myeloma (MM) is an incurable hematological malignancy with high chromosome instability and heavy dependence on the immunosuppressive bone marrow microenvironment. P53 mutations are adverse prognostic factors in MM; however, clinically, some patients without P53 mutations also exhibit aggressive disease progression. DNp73, an inhibitor of TP53 tumor suppressor family members, drives drug resistance and cancer progression in several solid malignancies. Nevertheless, the biological functions of DNp73 and the molecular mechanisms in myelomagenesis remain unclear. Methods: The effects of DNp73 on proliferation and drug sensitivity were assessed using flow cytometry and xenograft models. To investigate the mechanisms of drug resistance, RNA-seq and ChIP-seq analyses were performed in MM cell lines, with validation by Western blot and RT-qPCR. Immunofluorescence and transwell assays were used to assess DNA damage and cell invasion in MM cells. Additionally, in vitro phagocytosis assays were conducted to confirm the role of DNp73 in immune evasion. Results: Our study found that activation of NF-κB-p65 in multiple myeloma cells with different p53 mutation statuses upregulates DNp73 expression at the transcriptional level. Forced expression of DNp73 promoted aggressive proliferation and multidrug resistance in MM cells. Bulk RNA-seq analysis was conducted to assess the levels of MYCN, MYC, and CDK7. A ChIP-qPCR assay was used to reveal that DNp73 acts as a transcription factor regulating MYCN gene expression. Bulk RNA-seq analysis demonstrated increased levels of MYCN, MYC, and CDK7 with forced DNp73 expression in MM cells. A ChIP-qPCR assay revealed that DNp73 upregulates MYCN gene expression as a transcription factor. Additionally, DNp73 promoted immune evasion of MM cells by upregulating MYC target genes CD47 and PD-L1. Blockade of the CD47/SIRPα and PD-1/PD-L1 signaling pathways by the SIRPα-Fc fusion protein IMM01 and monoclonal antibody atezolizumab significantly restored the anti-MM activity of macrophages and T cells in the microenvironment, respectively. Discussion: In summary, our study demonstrated for the first time that the p53 family member DNp73 remarkably induces proliferation, drug resistance, and immune escape of myeloma cells by directly targeting MYCN and regulating the MYC pathway. The oncogenic function of DNp73 is independent of p53 status in MM cells. These data contribute to a better understanding of the function of TP53 and its family members in tumorigenesis. Moreover, our study clarified that DNp73 overexpression not only promotes aggressive growth of tumor cells but, more importantly, promotes immune escape of MM cells through upregulation of immune checkpoints. DNp73 could serve as a biomarker for immunotherapy targeting PD-L1 and CD47 blockade in MM patients.

Mechanisms, Function and Clinical Applications of Dnp73

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression

Progress in Investigation on P73 Gene and Human Tumorigenesis

The distinct role of CD73 in the progression of pancreatic cancer

Epigenetic modification in the expression of p73 p73 - epigenetic target for anticancer therapy

[Expression of ΔNp73 in Human NSCLC and Clinical Implication].

P73 Coordinates with Δ133p53 to Promote DNA Double-Strand Break Repair

Comprehensive Evaluation of NT5E/CD73 Expression and Its Prognostic Significance in Distinct Types of Cancers

p73 in Cancer

The Dual Role of P63 in Cancer

Targeting Post-Translational Modifications of the P73 Protein: A Promising Therapeutic Strategy for Tumors

A Systematic Pan-Cancer Analysis of PXDN As a Potential Target for Clinical Diagnosis and Treatment

Inhibition Of Tumor Suppressor P73 By Nerve Growth Factor Receptor Via Chaperone-Mediated Autophagy

Dual Role of p73 in Cancer Microenvironment and DNA Damage Response

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways

The Biological Characteristics of P73 in Hematological Malignancies

Effect of P73 Gene on Chemosensitivity of Human Lung Adenocarcinoma Cells H1299

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Expression and Clinical Significance of P73 in Colon Cancer

Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds